Risk of a decline in contract prices due to market maturity and competition among providers
First written in FY2016. 24 of 31 entries say "Restated". Latest entry: 2026-11-11.
Bml moved to the "Worse" side of this theme in 2026.
2 other companies' latest entry also says "Restated".
- FY2026WorsenedAnnual report
「Against this economic backdrop, the contract clinical testing industry is not in a fiscal year in which medical reimbursement rates are revised every 2 years. Although there was no reduction in medical reimbursement rates for specimen testing, the business environment remains challenging because, in addition to rising costs, the burden of securing personnel has increased against a backdrop of labor shortages.」
Although there was no reduction in medical reimbursement rates, the burden of securing personnel has increased due to labor shortages, in addition to rising costs, broadening the factors contributing to the challenging environment. - 2026-05-13WorsenedResults
「Although this is not a fiscal year in which reimbursement rates are revised, as such revisions are conducted every 2 years, and there was no reduction in reimbursement rates for laboratory tests, business conditions remain challenging due to rising costs of various kinds and the increasing burden of securing personnel amid labor shortages.」
診療報酬引下げがない一方、各種コスト上昇に加えて人材確保負担の増加が新たに明示され、厳しい事業環境の要因が広がっている。 - FY2026-H1RestatedAnnual report
「Against this economic backdrop, the contract clinical testing industry is not in a fiscal year in which medical reimbursement rates are revised every 2 years. Although there was no reduction in medical reimbursement rates for specimen testing, the business environment remains challenging because various costs, including labor costs, are rising and competition among providers continues.」
Although there was no reduction in medical reimbursement rates for specimen testing in the interim period, labor and other costs are rising and competition among providers continues, reconfirming the challenging business environment. - FY2025RestatedAnnual report
「Against this economic backdrop, the contract clinical testing industry is in a fiscal year in which medical reimbursement rates are revised every 2 years. In addition to lower medical reimbursement rates for specimen testing, the business environment remains challenging because labor and other costs are rising and competition among providers continues.」
Reconfirms the challenging environment arising from lower medical reimbursement rates for specimen testing, rising labor and other costs, and competition among providers. - FY2025-H1MaterialisedAnnual report
「Against this economic backdrop, 2024 is a fiscal year in which medical reimbursement rates are revised every 2 years. In addition to lower medical reimbursement rates for specimen testing, the business environment remains challenging because labor and other costs are rising and competition among providers continues.」
Lower 2024 medical reimbursement rates for specimen testing, rising labor and other costs, and competition among providers coexist as actual factors in the challenging business environment. - FY2024WorsenedAnnual report
「In addition to rising raw material and energy costs, competition among providers continues, and the business environment therefore remains challenging.」
In addition to the existing competition among providers, rising raw material and energy costs have been identified as factors contributing to the challenging environment for the clinical testing business. - FY2024-Q3RestatedAnnual report
「Against this economic backdrop, the contract clinical testing industry is not in a fiscal year in which medical reimbursement rates are revised every 2 years. Although there was no reduction in the reimbursement points for specimen testing (official prices), the business environment remains challenging because the number of COVID-19-related tests (hereinafter, “COVID tests”) has declined and competition among providers continues.」
Although there was no reduction in reimbursement points for specimen testing, the number of COVID tests has declined and competition among providers continues, reconfirming the challenging business environment. - FY2024-Q2RestatedAnnual report
「Against this economic backdrop, the contract clinical testing industry is not in a fiscal year in which medical reimbursement rates are revised every 2 years. Although there was no reduction in the reimbursement points for specimen testing (official prices), the business environment remains challenging because the number of COVID-19-related tests has declined and competition among providers continues.」
Although there was no reduction in reimbursement points for specimen testing in the quarter, the number of COVID-19-related tests has declined and competition among providers continues, reconfirming the challenging business environment. - FY2024-Q1RestatedAnnual report
「Against this economic backdrop, the contract clinical testing industry is not in a fiscal year in which medical reimbursement rates are revised every 2 years. Although there was no reduction in the reimbursement points for specimen testing (official prices), the business environment remains challenging because competition among providers continues.」
Although there was no reduction in reimbursement points for specimen testing in the quarter, competition among providers continues, reconfirming the challenging business environment. - FY2023-Q3RestatedAnnual report
「Against this economic backdrop, the number of patients visiting medical institutions has remained weak in the contract clinical testing industry due to the impact of medical reimbursement rate revisions and the spread of COVID-19. Competition with other companies in the industry also continues, and the business environment remains challenging.」
Reconfirms the challenging business environment resulting from medical reimbursement rate revisions, weak patient numbers and competition with other companies in the industry. - FY2023-Q2RestatedAnnual report
「Against this economic backdrop, the number of patients visiting medical institutions has remained weak in the contract clinical testing industry due to the impact of medical reimbursement rate revisions and the spread of COVID-19. Competition with other companies in the industry also continues, and the business environment remains challenging.」
States that medical reimbursement rate revisions, weak patient numbers and competition with other companies in the industry are causing the challenging business environment for contract clinical testing to persist. - FY2023-Q1RestatedAnnual report
「Against this backdrop, the business environment in the contract clinical testing industry remains challenging due to the impact of medical reimbursement rate revisions, patient numbers remaining weak, and continued competition with other companies in the industry.」
States that medical reimbursement rate revisions, weak patient numbers and competition with other companies in the industry coexist, and that the challenging business environment persists. - FY2022-Q3RestatedAnnual report
「Against this backdrop, although patient numbers in the contract clinical testing industry have remained weak due to the impact of COVID-19, the market has expanded as demand for COVID-19-related testing has grown. However, competition with other companies in the industry continues, and the business environment remains challenging.」
While the market has expanded due to COVID-19-related testing, patient numbers remain weak and competition with other companies in the industry continues, confirming the challenging business environment. - FY2021-Q2RestatedAnnual report
「However, the business environment remains challenging because intense competition among industry participants continues.」
Although patient avoidance of medical consultations following the spread of COVID-19 has begun to recover, the challenging business environment caused by intense competition among providers persists. - FY2021-Q1WorsenedAnnual report
「Against this backdrop, the business environment in the contract clinical testing industry remains challenging because the spread of COVID-19 has led patients to avoid or postpone medical consultations and intense competition among providers continues.」
States that, in addition to the existing intense competition among providers, patients have been avoiding or postponing medical consultations due to the spread of COVID-19, making the business environment for contract clinical testing even more challenging. - FY2020-Q3RestatedAnnual report
「Against this backdrop, although the contract clinical testing market is growing, the business environment remains challenging because intense competition among providers continues.」
Although the contract clinical testing market is growing, intense competition among providers continues and the challenging business environment persists. - FY2019RestatedAnnual report
「Contract clinical testing is susceptible to price competition because of the impact of healthcare policies, including government healthcare system reforms and revisions to medical reimbursement rates, as well as the large number of companies in a mature market. Competition among providers is also intensifying, and contract prices are therefore expected to remain weak going forward.」
Continues to describe the risk of declining contract prices due to market maturity, healthcare policy, price competition and competition among providers. - FY2019-Q3RestatedAnnual report
「Various healthcare system reforms are being implemented in the contract clinical testing industry to curb rising national healthcare expenditure. This fiscal year is one in which medical reimbursement rates, revised every 2 years, are being reviewed. Although reimbursement points for medical care as a whole were raised, those for specimen testing were reduced. In addition, the business environment remains challenging because intense competition among providers continues.」
Reiterates that the challenging business environment persists due to lower reimbursement points for specimen testing and intense competition among providers. - FY2019-Q2RestatedAnnual report
「Various healthcare system reforms are being implemented in the contract clinical testing industry to curb rising national healthcare expenditure. This fiscal year is one in which medical reimbursement rates, revised every 2 years, are being reviewed. Although reimbursement points for medical care as a whole were raised, those for specimen testing were reduced. In addition, the business environment remains challenging because intense competition among providers continues.」
Reiterates the reduction in reimbursement points for specimen testing and continued competition among providers as the current conditions underlying the risk of declining contract prices. - FY2019-Q2RestatedAnnual report
「Various healthcare system reforms are being implemented in the contract clinical testing industry to curb rising national healthcare expenditure. This fiscal year is one in which medical reimbursement rates, revised every 2 years, are being reviewed. Although reimbursement points for medical care as a whole were raised, those for specimen testing were reduced. In addition, the business environment remains challenging because intense competition among providers continues.」
Continues to describe the challenging business environment resulting from lower reimbursement points for specimen testing and intense competition among providers. Because the decline in specimen testing prices has already materialized, quantified is false and materialized is true. - FY2019-Q1MaterialisedAnnual report
「This fiscal year is one in which medical reimbursement rates, revised every 2 years, are being reviewed. Although reimbursement points for medical care as a whole were raised, those for specimen testing were reduced. In addition, the business environment remains challenging because intense competition among providers continues.」
States that reimbursement points for specimen testing were actually reduced and that intense competition among providers continues. - FY2018-Q3RestatedAnnual report
「The contract clinical testing industry is not in a fiscal year in which medical reimbursement rates are revised every 2 years. Although there was no reduction in the reimbursement points for specimen testing (official prices), the business environment remains challenging because competition among providers continues.」
Although there was no reduction in reimbursement points, competition among providers continues and the challenging business environment persists. - FY2018-Q2RestatedAnnual report
「The contract clinical testing industry is not in a fiscal year in which medical reimbursement rates are revised every 2 years. Although there was no reduction in the reimbursement points for specimen testing (official prices), the business environment remains challenging because competition among providers continues.」
Although there was no reduction in reimbursement points in the quarter, competition among providers continues and the challenging business environment persists. - FY2018-Q1RestatedAnnual report
「The contract clinical testing industry is not in a fiscal year in which medical reimbursement rates are revised every 2 years. Although there was no reduction in the reimbursement points for specimen testing (official prices), the business environment remains challenging because competition among providers continues.」
Although there was no reduction in reimbursement points in the quarter, competition among providers continues and the challenging business environment persists. - FY2017RestatedAnnual report
「The contract clinical testing industry is in a fiscal year in which medical reimbursement rates, revised every 2 years, are being reviewed. Although there was no significant overall reduction in the reimbursement points for specimen testing, the business environment remains challenging because intense competition among providers continues.」
Although there was no significant overall reduction in reimbursement points for specimen testing, intense competition among providers continues and the challenging business environment persists. - FY2017-Q3RestatedAnnual report
「The contract clinical testing industry is in a fiscal year in which medical reimbursement rates, revised every 2 years, are being reviewed. Although there was no significant overall reduction in the reimbursement points for specimen testing, the business environment remains challenging because competition among providers continues.」
Although there was no significant overall reduction in reimbursement points, the challenging business environment caused by competition among providers continues. - FY2017-Q2RestatedAnnual report
「The contract clinical testing industry is in a fiscal year in which medical reimbursement rates, revised every 2 years, are being reviewed. Although there was no significant overall reduction in the reimbursement points for specimen testing, the business environment remains challenging because competition among providers continues.」
Although there was no significant overall reduction in reimbursement points in the revision of medical reimbursement rates, the challenging business environment caused by competition among providers continues. - FY2017-Q1RestatedAnnual report
「The contract clinical testing industry is in a fiscal year in which medical reimbursement rates, revised every 2 years, are being reviewed. Although there was no significant overall reduction in the reimbursement points for specimen testing, the business environment remains challenging because competition among providers continues.」
States that although there was no significant reduction in reimbursement points, competition among providers continues and the challenging business environment persists. - FY2016First statedAnnual report
「Contract clinical testing is susceptible to price competition because of the impact of healthcare policies, including government healthcare system reforms and revisions to medical reimbursement rates, as well as the large number of companies in a mature market. Competition among providers is also intensifying, and contract prices are therefore expected to remain weak going forward.」
Explains that market maturity, the large number of companies and intensifying competition are behind the decline in contract prices.